Skip to main content
. 2020 Mar 30;91(6):622–630. doi: 10.1136/jnnp-2019-322038

Table 6.

Group 2. Average annual mean change in score for pre-antidopaminergic and post-antidopaminergic takers and matched controls (SD in brackets)

Control group
(time 1)
(n=103)
Control group
(time 2)
(n=103)
P value Cohen’s d Pre-antidopaminergic medication
(time 1)
(n=90)
Post-antidopaminergic
Medication
(time 2)
(n=90)
P value Cohen’s d
UHDRS total motor score 2.4
(7.9)
2.7
(7.6)
0.819 0.04 5.7
(11.2)
2.9
(9.2)
0.079 0.27
UHDRS total chorea score 0.4
(4.5)
1
(4.2)
0.344 0.14 1.1
(4.7)
−0.5*
(5.5)
0.036 0.31
UHDRS saccade initiation 0.4
(1.4)
0.1
(1.4)
0.100 0.21 0.6
(1.5)
0.03*
(1.7)
0.020 0.35
Irritability
(PBA)
0.4
(4)
0.6
(3.4)
0.745 0.05 0.1
(6.2)
−1.8
(6.2)
0.065 0.31
Depression
(PBA)
−0.1
(4.1)
−0.1
(4.5)
0.962 0 0.8
(6.2)
−0.2
(6.7)
0.508 0.2
Apathy
(PBA)
0.02
(2.9)
0.3
(3.3)
0.474 0.09 0.3
(4)
0.9
(4.9)
0.396 0.13
Total composite cognitive z-score 0.4
(3.9)
−0.3
(4)
0.199 0.18 0.8
(3.4)
−0.7***
(3.4)
0.001 0.44
TFC score −0.6
(1.3)
−0.4
(1.6)
0.483 0.13 −0.9
(1.8)
−1
(1.6)
0.664 0.05
UHDRS independence scale −3.1
(7.6)
−1.8
(9.5)
0.3 0.15 −5.2
(9.5)
−3.6
(7.3)
0.183 0.18

P values are from paired t-tests.

*Indicates a significant difference (p<0.005) when compared with the control non-antidopaminergic medication group.

†Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic medication group.

PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.